Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Sadarangani gave a talk on the body's immune response to novel vaccines at the Winter Science Meeting 2015 at the Academy of Medical Sciences this month. His efforts to make the talk accessible and engage with a lay audience won him the Communications Prize.

The summary of Dr Sadarangani's project:

What is this project about? There are 500,000 cases of meningococcal disease (blood poisoning and meningitis) per year worldwide, and 1 in 10 people will die. A new meningococcal vaccine introduced in the UK in 2015 includes part of the bacterial membrane, known as an outer membrane vesicle or OMV. In this study we immunised 26 healthy adults with 3 doses of a new vaccine (MenPF) which also contains OMV. We tested their blood to look at how they responded to the vaccine and which genes were switched ‘on’ or ‘off’ after vaccination. 

Why is it important? We need to know more about vaccines which contain OMV to understand how to make better vaccines in the future - at the moment they often cause fever, and multiple doses are needed. No one has previously used genetic studies to address this.

What were the results? All participants responded well to the vaccine and had high antibody levels after 3 doses. Specific genes involved in injury and inflammation were switched on or off within 4-6 hours after the 1st dose. This tells us, for the first time, what is happening in the body very early after vaccination. A different set of genes were switched on or off 24 hours after the 3rd dose, and these are involved in a specific type of the body’s immune response. This information tells us exactly what is happening after vaccination and we may be able to use this to design better vaccines in the future, which cause fewer side effects and work better.

Similar stories

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation.

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.